

Hyloris partners with Huons to introduce dental products in South Korea

22 August 2025 | News

XTRAZA is a proprietary oral rinse formulated to deliver tranexamic acid for oral cavity



Belgium's Hyloris Pharmaceuticals SA, has announced that an exclusive license and supply agreement has been signed with Huons Co. for XTRAZA. Under the terms of the agreement, Hyloris will exclusively supply XTRAZA in South Korea to Huons.

XTRAZA is a proprietary oral rinse formulated to deliver tranexamic acid - an antifibrinolytic agent - directly to the oral cavity. It is intended for use in patients taking anticoagulant therapies (blood thinners) who are undergoing dental procedures with a risk of bleeding, such as tooth extractions. While tranexamic acid has a well-established track record in various dosage forms for minimising or preventing postoperative bleeding, XTRAZA introduces a novel, localized delivery method optimized to promote effective coagulation during and after dental interventions.

South Korea's dental market offers a strong opportunity for XTRAZA, supported by significant procedural volumes and a highly developed healthcare infrastructure. In 2022, the country recorded 60.5 million dental procedures, with the dental consumables market valued at \$2.01 billion in 2023 and projected to reach \$3.33 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 7.4%¹. The nation has 35,000 licensed dentists (as of 2024), expected to grow by 1.8-2.4% annually, with 64 dentists per 10,000 people, among the highest ratios globally.